Adamas Announces New Employment Inducement Grant
August 14, 2020 16:04 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three...
Adamas Reports Second Quarter 2020 Financial Results
August 06, 2020 16:02 ET
|
Adamas Pharmaceuticals, Inc.
Second quarter 2020 GOCOVRI® product sales of $18.0 million, a 41% increase over second quarter 2019 Total paid prescriptions grew to 8,150, a 32% increase over second quarter 2019 EMERYVILLE,...
Adamas to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020
July 23, 2020 16:02 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday,...
Adamas presents new post-hoc Phase 3 data analysis for GOCOVRI® in Parkinson’s disease at the 2020 American Academy of Neurology (AAN) Science Highlights Platform
July 15, 2020 08:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to...
Adamas Announces New Employment Inducement Grant
July 10, 2020 16:05 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., July 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three...
Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment
June 17, 2020 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes
June 04, 2020 16:30 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
Adamas to Present at Upcoming William Blair Conference
June 03, 2020 16:01 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...
Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson’s disease - expands coverage with reduction of ‘OFF’ time and increased ‘good ON’ time
May 13, 2020 09:15 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to...
Adamas Announces New Employment Inducement Grant
May 08, 2020 18:46 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new...